Is asenapine or aripiprazole more effective than a placebo for reducing episodes of mania in children with bipolar I disorder
Year: 2018
Type: article
Abstract: Objective: The objective of this selective EBM review is to determine whether or not asenapine or aripiprazole are more effective than a placebo for reducing episodes of mania in children with bipolar I disorder. Study Design: Review of two randomized control trials (RCTs) published in 2013 and 2015, and a flexible-dose, open-label, extension study published in 2016. Data Sources: Each article used was published in English and found using PubMed database. All articles were published in peer-reviewed journals. Outcomes Measured: The clinical superiority of asenapine and aripiprazole were measured by a change in baseline in the Young Mania Rating Scale (YMRS) total score. A decrease in YMRS score indicates improved mania symptoms. Results: Findling, et al. (2015) found that all studied doses of asenapine were more effective than a placebo at reducing the baseline score of the Young Mania Rating Scale (YMRS) [for 2.5 mg: -12.8 vs -9.6, p=0.008; for 5mg -14.9 vs -9.6, p <0.001; for 10mg: - 15.8 vs -9.6, p <0.001]. Findling, et al. (2013) found that all doses of aripiprazole were more effective than a placebo using the same YMRS change from baseline [for 10mg: - 14.1 vs -8.2, p <0.001; for 30 mg: -14.9 vs -8.2, p <0.001]. This article also examined the average time to withdrawal [for 10 mg 15.6 weeks vs 5.3, p <0.001; for 30 mg 9.5 vs 5.3, p <0.05]. The Findling, et al. (2016) open-label, extension study found that there was a greater mean change in baseline YMRS total scores in the placebo/asenapine population (-13.0 at 26 weeks and -15.2 at 50 weeks), a 79.2% total population of patients that were YMRS 50% responders, and 68.5% of all patients achieved YMRS remission. Conclusions: Though each study reported an improvement of symptoms, the efficacy of asenapine and aripiprazole over a placebo for the treatment of mania episodes in children with bipolar I disorder cannot be determined due to the limitations in experimental design and validity.
Author: Nicole Silva
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Keywords: asenapine, aripiprazole, bipolar I disorder, pediatric bipolar disorder, mania, Young Mania Rating Scale, antipsychotic efficacy, placebo comparison, dose comparison, treatment response rate, adverse events, antipsychotic tolerability, atypical antipsychotics, children and adolescents, antipsychotic safety
Open Access status: green
OpenAlex ID: W2909994503
